Right now , for my own purposes , I am discounting the market cap as a none meaningful factor till results are released. What I see driving NTRP is the science for a disease that has so far medical science has not been able to address and indications are that NTRP has something. Other factors , like a low float , applying for an up listing , cash on hand to carry them into 2018 , and warrants that if exercised will put another $50 MILLION in the coffer with little dilution help.
The multibagger part comes or doesn't come with the April results release and a partnership. That's what I see for now. In two months I believe we will all know.